alk5 target Search Results


alk5  (R&D Systems)
94
R&D Systems alk5
BMP9 and TGF-β signaling is increased during the tumor progression pathway of the RIP1-Tag2 model. (a–d) Quantitative RT-PCR analysis of the expression of ALK1 (a) and <t>ALK5</t> (b) receptors and TGF-β (c) and BMP9 (d) ligands in pancreatic islets from progressive tumor stages in RIP1-Tag2 mice (materials pooled from >20 mice per tumor stage, analysis independently performed at least three times). Error bars show the mean ± SD. (e–h) Immunostaining for ALK1 (red; e), ALK5 (red; f), TGF-β (red; g), and BMP9 (red; h) of sections from the pancreas of RIP1-Tag2 mice. As a comparison, immunostaining for the endothelial cell marker podocalyxin (green) was performed in e and for CD31 (green) in f. The angiogenic islet lesional area is outlined by white dashes. Bars, 50 µm.
Alk5, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/alk5/product/R&D Systems
Average 94 stars, based on 1 article reviews
alk5 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
aurka tpx2  (Carna Inc)
96
Carna Inc aurka tpx2
BMP9 and TGF-β signaling is increased during the tumor progression pathway of the RIP1-Tag2 model. (a–d) Quantitative RT-PCR analysis of the expression of ALK1 (a) and <t>ALK5</t> (b) receptors and TGF-β (c) and BMP9 (d) ligands in pancreatic islets from progressive tumor stages in RIP1-Tag2 mice (materials pooled from >20 mice per tumor stage, analysis independently performed at least three times). Error bars show the mean ± SD. (e–h) Immunostaining for ALK1 (red; e), ALK5 (red; f), TGF-β (red; g), and BMP9 (red; h) of sections from the pancreas of RIP1-Tag2 mice. As a comparison, immunostaining for the endothelial cell marker podocalyxin (green) was performed in e and for CD31 (green) in f. The angiogenic islet lesional area is outlined by white dashes. Bars, 50 µm.
Aurka Tpx2, supplied by Carna Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/aurka tpx2/product/Carna Inc
Average 96 stars, based on 1 article reviews
aurka tpx2 - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
primary antibodies targeted against tgfβr1/alk-5  (Novus Biologicals)
90
Novus Biologicals primary antibodies targeted against tgfβr1/alk-5
BMP9 and TGF-β signaling is increased during the tumor progression pathway of the RIP1-Tag2 model. (a–d) Quantitative RT-PCR analysis of the expression of ALK1 (a) and <t>ALK5</t> (b) receptors and TGF-β (c) and BMP9 (d) ligands in pancreatic islets from progressive tumor stages in RIP1-Tag2 mice (materials pooled from >20 mice per tumor stage, analysis independently performed at least three times). Error bars show the mean ± SD. (e–h) Immunostaining for ALK1 (red; e), ALK5 (red; f), TGF-β (red; g), and BMP9 (red; h) of sections from the pancreas of RIP1-Tag2 mice. As a comparison, immunostaining for the endothelial cell marker podocalyxin (green) was performed in e and for CD31 (green) in f. The angiogenic islet lesional area is outlined by white dashes. Bars, 50 µm.
Primary Antibodies Targeted Against Tgfβr1/Alk 5, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/primary antibodies targeted against tgfβr1/alk-5/product/Novus Biologicals
Average 90 stars, based on 1 article reviews
primary antibodies targeted against tgfβr1/alk-5 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
sb431542 (targeting the alk4/alk5/alk7 family (inman et al., 2002))  (STEMCELL Technologies Inc)
90
STEMCELL Technologies Inc sb431542 (targeting the alk4/alk5/alk7 family (inman et al., 2002))
BMP9 and TGF-β signaling is increased during the tumor progression pathway of the RIP1-Tag2 model. (a–d) Quantitative RT-PCR analysis of the expression of ALK1 (a) and <t>ALK5</t> (b) receptors and TGF-β (c) and BMP9 (d) ligands in pancreatic islets from progressive tumor stages in RIP1-Tag2 mice (materials pooled from >20 mice per tumor stage, analysis independently performed at least three times). Error bars show the mean ± SD. (e–h) Immunostaining for ALK1 (red; e), ALK5 (red; f), TGF-β (red; g), and BMP9 (red; h) of sections from the pancreas of RIP1-Tag2 mice. As a comparison, immunostaining for the endothelial cell marker podocalyxin (green) was performed in e and for CD31 (green) in f. The angiogenic islet lesional area is outlined by white dashes. Bars, 50 µm.
Sb431542 (Targeting The Alk4/Alk5/Alk7 Family (Inman Et Al., 2002)), supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sb431542 (targeting the alk4/alk5/alk7 family (inman et al., 2002))/product/STEMCELL Technologies Inc
Average 90 stars, based on 1 article reviews
sb431542 (targeting the alk4/alk5/alk7 family (inman et al., 2002)) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
alk5 target  (AstraZeneca ltd)
90
AstraZeneca ltd alk5 target
BMP9 and TGF-β signaling is increased during the tumor progression pathway of the RIP1-Tag2 model. (a–d) Quantitative RT-PCR analysis of the expression of ALK1 (a) and <t>ALK5</t> (b) receptors and TGF-β (c) and BMP9 (d) ligands in pancreatic islets from progressive tumor stages in RIP1-Tag2 mice (materials pooled from >20 mice per tumor stage, analysis independently performed at least three times). Error bars show the mean ± SD. (e–h) Immunostaining for ALK1 (red; e), ALK5 (red; f), TGF-β (red; g), and BMP9 (red; h) of sections from the pancreas of RIP1-Tag2 mice. As a comparison, immunostaining for the endothelial cell marker podocalyxin (green) was performed in e and for CD31 (green) in f. The angiogenic islet lesional area is outlined by white dashes. Bars, 50 µm.
Alk5 Target, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/alk5 target/product/AstraZeneca ltd
Average 90 stars, based on 1 article reviews
alk5 target - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


BMP9 and TGF-β signaling is increased during the tumor progression pathway of the RIP1-Tag2 model. (a–d) Quantitative RT-PCR analysis of the expression of ALK1 (a) and ALK5 (b) receptors and TGF-β (c) and BMP9 (d) ligands in pancreatic islets from progressive tumor stages in RIP1-Tag2 mice (materials pooled from >20 mice per tumor stage, analysis independently performed at least three times). Error bars show the mean ± SD. (e–h) Immunostaining for ALK1 (red; e), ALK5 (red; f), TGF-β (red; g), and BMP9 (red; h) of sections from the pancreas of RIP1-Tag2 mice. As a comparison, immunostaining for the endothelial cell marker podocalyxin (green) was performed in e and for CD31 (green) in f. The angiogenic islet lesional area is outlined by white dashes. Bars, 50 µm.

Journal: The Journal of Experimental Medicine

Article Title: Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis

doi: 10.1084/jem.20091309

Figure Lengend Snippet: BMP9 and TGF-β signaling is increased during the tumor progression pathway of the RIP1-Tag2 model. (a–d) Quantitative RT-PCR analysis of the expression of ALK1 (a) and ALK5 (b) receptors and TGF-β (c) and BMP9 (d) ligands in pancreatic islets from progressive tumor stages in RIP1-Tag2 mice (materials pooled from >20 mice per tumor stage, analysis independently performed at least three times). Error bars show the mean ± SD. (e–h) Immunostaining for ALK1 (red; e), ALK5 (red; f), TGF-β (red; g), and BMP9 (red; h) of sections from the pancreas of RIP1-Tag2 mice. As a comparison, immunostaining for the endothelial cell marker podocalyxin (green) was performed in e and for CD31 (green) in f. The angiogenic islet lesional area is outlined by white dashes. Bars, 50 µm.

Article Snippet: After blocking using serum-free protein block (Dako) for 90 min at room temperature (for PAI-1 staining, the Mouse-on-mouse immunodetection kit [Vector Laboratories] was used), sections were incubated overnight at 4°C with primary antibodies directed against BMP9 (ab35088; dilution, 1:500; Abcam), TGF-β (sc-146; dilution, 1:500; Santa Cruz Biotechnology, Inc.), ALK5 (AF3025; dilution, 1:25; R&D Systems), CD31 (MEC13.3; dilution, 1:100; BD), PAI-1 (Clone 41; dilution, 1:100; BD), or NG2 (AB5320; dilution, 1:400; Millipore) in PBS supplemented with 1% BSA.

Techniques: Quantitative RT-PCR, Expressing, Immunostaining, Comparison, Marker

Both ALK1 and ALK5 target gene expression is down-regulated by blunted ALK1 signaling. (a–c) Id1 (a), Id3 (b), and PAI-1 (c) mRNA expression in tumors from RIP1-Tag2; Alk1 +/− mice compared with that of WT littermates at 12 wk of age, as well as RIP1-Tag2 mice treated with control F c (Ctrl F c ) protein or RAP-041 between 10 and 12 wk of age. The values for each gene represent mean and SD of at least three independent experiments with three to seven tumors per experimental condition. (d) Expression of PAI-1 mRNA in MS1 endothelial cells treated with TGF-β, BMP9, RAP-041, SB431542, and combinations thereof. Error bars show the mean ± SD. (e) Western blot analysis of PAI-1 protein levels and phosphorylated Smad2 (pSmad2) levels in lysates from MS1 cells subjected to single or combined stimulation of TGF-β and BMP9. Relative expression levels were calculated by densitometric quantification of PAI-1 or pSmad2 relative to the reference protein calnexin. All analyses were independently performed at least three times.

Journal: The Journal of Experimental Medicine

Article Title: Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis

doi: 10.1084/jem.20091309

Figure Lengend Snippet: Both ALK1 and ALK5 target gene expression is down-regulated by blunted ALK1 signaling. (a–c) Id1 (a), Id3 (b), and PAI-1 (c) mRNA expression in tumors from RIP1-Tag2; Alk1 +/− mice compared with that of WT littermates at 12 wk of age, as well as RIP1-Tag2 mice treated with control F c (Ctrl F c ) protein or RAP-041 between 10 and 12 wk of age. The values for each gene represent mean and SD of at least three independent experiments with three to seven tumors per experimental condition. (d) Expression of PAI-1 mRNA in MS1 endothelial cells treated with TGF-β, BMP9, RAP-041, SB431542, and combinations thereof. Error bars show the mean ± SD. (e) Western blot analysis of PAI-1 protein levels and phosphorylated Smad2 (pSmad2) levels in lysates from MS1 cells subjected to single or combined stimulation of TGF-β and BMP9. Relative expression levels were calculated by densitometric quantification of PAI-1 or pSmad2 relative to the reference protein calnexin. All analyses were independently performed at least three times.

Article Snippet: After blocking using serum-free protein block (Dako) for 90 min at room temperature (for PAI-1 staining, the Mouse-on-mouse immunodetection kit [Vector Laboratories] was used), sections were incubated overnight at 4°C with primary antibodies directed against BMP9 (ab35088; dilution, 1:500; Abcam), TGF-β (sc-146; dilution, 1:500; Santa Cruz Biotechnology, Inc.), ALK5 (AF3025; dilution, 1:25; R&D Systems), CD31 (MEC13.3; dilution, 1:100; BD), PAI-1 (Clone 41; dilution, 1:100; BD), or NG2 (AB5320; dilution, 1:400; Millipore) in PBS supplemented with 1% BSA.

Techniques: Targeted Gene Expression, Expressing, Control, Western Blot

List of primers used for quantitative RT-PCR

Journal: The Journal of Experimental Medicine

Article Title: Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis

doi: 10.1084/jem.20091309

Figure Lengend Snippet: List of primers used for quantitative RT-PCR

Article Snippet: After blocking using serum-free protein block (Dako) for 90 min at room temperature (for PAI-1 staining, the Mouse-on-mouse immunodetection kit [Vector Laboratories] was used), sections were incubated overnight at 4°C with primary antibodies directed against BMP9 (ab35088; dilution, 1:500; Abcam), TGF-β (sc-146; dilution, 1:500; Santa Cruz Biotechnology, Inc.), ALK5 (AF3025; dilution, 1:25; R&D Systems), CD31 (MEC13.3; dilution, 1:100; BD), PAI-1 (Clone 41; dilution, 1:100; BD), or NG2 (AB5320; dilution, 1:400; Millipore) in PBS supplemented with 1% BSA.

Techniques: